IPX-461, also known as Patinavir, is a small molecule inhibitor that targets a specific protein involved in various cellular processes. The compound was initially developed by a team of researchers at a leading pharmaceutical company, with the goal of creating a novel therapeutic agent for the treatment of several debilitating diseases.

The versatility of IPX-461 lies in its potential to treat a range of diseases across various therapeutic areas. Some of the most promising applications of IPX-461 include: